Kairos Pharma, LTD. (KAPA) shareholders
KAPANYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$0.40−0.01 (-1.70%)
Close on Nov 17, 2026Market cap $1.49MP/E –Yield –
Ownership
Who owns Kairos Pharma's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| John S. Yu | CEO and Chairman, Director, 10% owner | 5,546,677 | 23.41% | Nov 26, 2025 |
| Neil Bhowmick | Chief Scientific Officer | 1,311,739 | 5.54% | Dec 30, 2025 |
| Doug Samuelson | Chief Financial Officer | 293,039 | 1.24% | Nov 26, 2025 |
| Ramachandran Murali | VP of Research and Development | 299,529 | 1.26% | Nov 26, 2025 |
| Hyun W. Bae | Director | 73,370 | 0.31% | Dec 23, 2025 |
| Rahul Singhvi | Director | 49,204 | 0.21% | Nov 26, 2025 |
| Hansoo Michael Keyoung | Director | 29,084 | 0.12% | Nov 26, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Neil Bhowmick Chief Scientific Officer | Oct 8, 2025 | Award | +171,756 | – | – | 1,311,739 |
| Hyun W. Bae Director | Oct 8, 2025 | Award | +19,084 | – | – | 73,370 |
| Rahul Singhvi Director | Oct 8, 2025 | Award | +19,084 | – | – | 49,204 |
| Hansoo Michael Keyoung Director | Oct 8, 2025 | Award | +19,084 | – | – | 29,084 |
| Doug Samuelson Chief Financial Officer | Oct 8, 2025 | Award | +152,672 | – | – | 293,039 |
| Ramachandran Murali VP of Research and Development | Oct 8, 2025 | Award | +152,672 | – | – | 299,529 |
| John S. Yu CEO and Chairman, Director, 10% owner | Oct 8, 2025 | Award | +190,840 | – | – | 230,105 |
| Hyun W. Bae Director | Sep 16, 2025 | Award | +10,000 | – | – | 54,286 |
| Hansoo Michael Keyoung Director | Sep 16, 2025 | Award | +10,000 | – | – | 10,000 |
| Neil Bhowmick Chief Scientific Officer | Jan 1, 2025 | Award | +14,000 | – | – | 1,139,983 |
| John S. Yu CEO and Chairman, Director, 10% owner | Jan 1, 2025 | Award | +14,000 | – | – | 5,355,838 |
| Ramachandran Murali VP of Research and Development | Jan 1, 2025 | Award | +14,000 | – | – | 147,057 |
| Ramachandran Murali VP of Research and Development | Nov 25, 2024 | Buy | +200 | $1.59 | $318 | 133,057 |
| Doug Samuelson Chief Financial Officer | Nov 22, 2024 | Buy | +2,500 | $1.50 | $3.75K | 60,796 |
| John S. Yu CEO and Chairman, Director, 10% owner | Nov 20, 2024 | Buy | +4,000 | $1.44 | $5.76K | 5,341,837 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of shares outstanding
2.26%
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
-37.5%
From 0M shares
Short volume, 20 days
23.0%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Kairos Pharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 49,276 shares on Oct 7, 2026 over the last 90 days.
See a number that looks wrong?